Plain-English translation of NCT07613385 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new approach to treating relapsed or refractory acute myeloid leukemia (AML) — a type of blood cancer that has come back or stopped responding to earlier treatment. Doctors will take samples of your cancer cells and test them against about 135 different drugs and drug combinations in the laboratory to see which ones work best against your specific cancer. They will also run genetic tests on your cells to understand what's driving your cancer, and then use all this information together to recommend personalized treatment options designed just for you.
Most patients with AML that has relapsed or stopped responding to treatment have limited options, and doctors often have to guess which drugs might work next. This trial exists to see whether testing your actual cancer cells against many drugs before treatment begins can help doctors make smarter, more personalized choices and improve your chances of getting a treatment that actually works.
You likely qualify if…
You likely don't qualify if…
You will have bone marrow and blood samples taken to test against multiple drugs in the laboratory and to perform genetic analysis — this typically happens once at the beginning of the study. The lab work takes about 5–14 days, and during that time a team of doctors will review all the test results and genetic information to create personalized treatment recommendations for you. You will then receive follow-up communication about the recommended treatment options, though the actual treatment decisions and next steps will be made with your own doctors.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States